
ALT Panel A shows the incidence of a composite of death from any cause, stroke, or myocardial infarction (the primary outcome). Panel B shows the incidence of major bleeding (the major secondary outcome), which was defined as a bleeding event of Bleeding Academic Research Consortium type 3 (nonfatal major bleeding) or 5 (fatal bleeding).

ALT A table showing the clinical end points at 1 year (intention-to-treat analysis). It compares two groups: Ticagrelor-Policy Group (9444 patients) and Prasugrel-Policy Group (7651 patients). Primary end point shows 1113 events in the Ticagrelor-Policy Group and 848 in the Prasugrel-Policy Group. Secondary end points are listed, including death from any cause, myocardial infarction, stroke, major bleeding, and stent thrombosis, with corresponding patient numbers and percentages for each group. Odds ratios with confidence intervals are provided.













